RecruitingNCT05270499

Aveir VR Real-World Evidence Post-Approval Study

Aveir Single-Chamber Leadless Pacemaker Real-World Evidence Post-Approval Study

Sponsor

Abbott Medical Devices

Enrollment

2,100 participants

Start Date

Jun 21, 2022

Study Type

OBSERVATIONAL

Conditions

Arrythmia Bradycardia Cardiac Pacemaker

Summary

The purpose of this post-approval study is to evaluate the long-term safety of the single-chamber Aveir VR leadless pacemaker using real-world evidence methods.

Eligibility

Min Age: 18 Years

Inclusion Criteria4

Eligibility Criteria:
Implanted with an Aveir VR leadless pacemaker
Continuous enrollment in Medicare Part A and Part B for 12 months prior to implant and for 30 days after implant, except in the case of death within the 30-day period
Ability to link with Medicare fee-for-service data

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEAveir VR Leadless Pacemaker System

This study will utilize real-world data from patients implanted with the Aveir VR Leadless Pacemaker System. No device intervention will be conducted in this study.